Cover Image
市場調查報告書

全球氣喘、慢性阻塞性肺病治療藥市場競爭分析

A Competitive Analysis of the Global Asthma and COPD Therapeutics Market

出版商 Frost & Sullivan 商品編碼 318243
出版日期 內容資訊 英文 69 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球氣喘、慢性阻塞性肺病治療藥市場競爭分析 A Competitive Analysis of the Global Asthma and COPD Therapeutics Market
出版日期: 2014年10月30日 內容資訊: 英文 69 Pages
簡介

氣喘、慢性阻塞性肺病的治療藥,粗略地劃分為支氣管擴張藥和抗發炎劑,這些聯合治療等。新型的吸入器和劑型、抗發炎劑等開發,成為氣喘、慢性阻塞性肺病治療藥市場的推動因素。

本報告提供全球各國氣喘及慢性阻塞性肺病(以下慢性阻塞性肺病)的已上市/臨床實驗中的治療藥及聯合治療相關分析、臨床實驗的整體進展調查,及今後的發展預測(時間表),過去的產品上市趨勢與今後的上市預定,各藥物等級、各種類的詳細趨勢等。

第1章 摘要整理

  • 主要調查結果
  • 主要調查結果:氣喘
  • 主要調查結果:慢性阻塞性肺病
  • 產品開始及藥物候補開發概要
  • 值得注意的主要企業
  • CEO全方位展望

第2章 調查手法及範圍

  • 調查手法及範圍

第3章 市場概要

  • 市場概要:區分
  • 市場概要:定義
  • 氣喘的盛行率:各國各地區
  • 慢性阻塞性肺病的盛行率:各國各地區

第4章 氣喘及慢性阻塞性肺病的競爭情形

  • 氣喘治療藥市場:已上市/開發中產品
  • 氣喘治療藥市場:主要的已上市產品的概要
  • 氣喘治療藥市場:主要的開發中產品的概要
  • 慢性阻塞性肺病治療藥市場:已上市/開發中產品
  • 慢性阻塞性肺病治療藥市場:主要的已上市產品的概要
  • 慢性阻塞性肺病治療藥市場:主要的開發中產品的概要

第5章 活動時間軸

  • 氣喘、慢性阻塞性肺病治療藥整體市場:主要開發中產品的上市預定開發平台
  • 重要度高的第Ⅲ相實驗
  • 產品上市估計時間表:氣喘、慢性阻塞性肺病用Striverdi Respimat(Boehringer Ingelheim)
  • 產品上市估計時間表:氣喘用Quilizumab(Genentech)
  • 產品上市估計時間表:氣喘、慢性阻塞性肺病用DuoResp Spiromax(Teva Pharmaceuticals)
  • 產品上市估計時間表:慢性阻塞性肺病用DIncruse Ellipta(umekurijiniumu)(GSK)
  • 產品上市估計時間表:氣喘用Benralizumab(AstraZeneca)
  • 專利失效時間表

第6章 產品開發動態即時看板系統:已上市、核准及第三階段產品

  • Seebri Breezhaler(Novartis)
  • Advair/Seretide(GSK)
  • Xolair(Genentech and Novartis)
  • Asmanex Twisthaler(Merck & Co.)
  • piriva(Boehringer Ingelheim)
  • AirFlu Sal/Forspiro(Sandoz (Novartis))
  • Incruse Ellipta(GSK)
  • Benralizumab(AstraZeneca)
  • Bosatria(GSK)
  • PT003(Pearl Therapeutics (AstraZeneca))

第7章 結論

  • 結論
  • 法律上的免責聲明

第8章 附錄

  • 決策依據的資料庫:全球吸煙者數
  • 決策依據的資料庫:慢性阻塞性肺病患者人口

第9章 關於FROST & SULLIVAN

目錄
Product Code: MA2A-01-00-00-00

Novel Inhaler Devices and Formulations are Impetuses for Growth

The research service assesses marketed and investigational products, as well as combination regimens, for asthma and chronic obstructive pulmonary disease (COPD). Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into bronchodilators, anti-inflammatories, and combination therapies of current global interest. Novel inhaler devices, formulations, and anti-inflammatories are key drivers for the market.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Key Findings
  • 2. Key Findings-Asthma
  • 3. Key Findings-COPD
  • 4. Overview of Product Launches and Pipeline Development
  • 5. Key Companies to Watch
  • 6. CEO's Perspective

2. METHODOLOGY AND SCOPE

  • 1. Methodology and Scope

3. MARKET OVERVIEW

  • 1. Market Overview-Segmentation
  • 2. Market Overview-Definitions
  • 3. Prevalence of Asthma by Country/Region
  • 4. Prevalence of COPD by Country/Region

4. ASTHMA AND COPD COMPETITIVE LANDSCAPE

  • 1. Asthma Therapeutics Market-Marketed and Pipeline Products
  • 2. Asthma Therapeutics Market-Marketed and Pipeline Products (continued)
  • 3. Asthma Therapeutics Market-Key Marketed Product Synopsis
  • 4. Asthma Therapeutics Market-Key Marketed Product Synopsis (continued)
  • 5. Asthma Therapeutics Market-Key Pipeline Product Synopsis
  • 6. Asthma Therapeutics Market-Key Pipeline Product Synopsis (continued)
  • 7. COPD Therapeutics Market-Marketed and Pipeline Products
  • 8. COPD Therapeutics Market-Marketed and Pipeline Products (continued)
  • 9. COPD Therapeutics Market-Key Marketed Product Synopsis
  • 10. COPD Therapeutics Market-Key Marketed Product Synopsis (continued)
  • 11. COPD Therapeutics Market-Key Pipeline Product Synopsis
  • 12. COPD Therapeutics Market-Key Pipeline Product Synopsis (continued)

5. EVENT TIMELINES

  • 1. Total Asthma and COPD Therapeutics Market-Projected Launch Timeline for Key Pipeline Drugs
  • 2. Pivotal Phase 3 Trials
  • 3. Estimated Product Launch Timeline-Striverdi Respimat for Asthma and COPD by Boehringer Ingelheim
  • 4. Estimated Product Launch Timeline-Quilizumab for Asthma by Genentech
  • 5. Estimated Product Launch Timeline-DuoResp Spiromax for Asthma and COPD by Teva Pharmaceuticals
  • 6. Estimated Product Launch Timeline-Incruse Ellipta (umeclidinium) for COPD by GSK
  • 7. Estimated Product Launch Timeline-Benralizumab for Asthma by AstraZeneca
  • 8. Patent Expiration Timeline

6. PRODUCT DASHBOARDS-MARKETED, APPROVED, AND PHASE 3 PRODUCTS

  • 1. Seebri Breezhaler by Novartis
  • 2. Advair/Seretide by GSK
  • 3. Xolair by Genentech and Novartis
  • 4. Asmanex Twisthaler by Merck & Co.
  • 5. Spiriva by Boehringer Ingelheim
  • 6. AirFlu Sal/Forspiro by Sandoz (Novartis)
  • 7. Incruse Ellipta by GSK
  • 8. Benralizumab by AstraZeneca
  • 9. Bosatria by GSK
  • 10. PT003 by Pearl Therapeutics (AstraZeneca)

7. CONCLUSIONS

  • 1. Conclusions
  • 2. Legal Disclaimer

8. APPENDIX

  • 1. Decision Support Database-Global Prevalence of Smokers
  • 2. Decision Support Database-Global Prevalence of Smokers (continued)
  • 3. Decision Support Database-Population with COPD
  • 4. Decision Support Database-Population with COPD (continued)

9. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top